Media headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the pharmaceutical company an impact score of 44.9635094894598 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX) – Lookout for Volatility – Stock Watch (stocksnewstimes.com)
- Investors need to focus on Analysts Rating: Vertex Pharmaceuticals Incorporated (VRTX) – Wall Street Morning (wallstreetmorning.com)
- Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in Stock (americanbankingnews.com)
- Vertex to Present at the Cowen Healthcare Conference on March 13 (finance.yahoo.com)
- Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million (americanbankingnews.com)
A number of equities research analysts have commented on the company. BidaskClub raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. TheStreet raised Vertex Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, March 2nd. Maxim Group raised their price objective on Vertex Pharmaceuticals from $195.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, March 5th. Argus set a $194.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, February 23rd. They noted that the move was a valuation call. Finally, Zacks Investment Research cut Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and twenty-five have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $183.96.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 EPS for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.08. The business had revenue of $651.63 million for the quarter, compared to analyst estimates of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. Vertex Pharmaceuticals’s quarterly revenue was up 42.1% compared to the same quarter last year. During the same period last year, the company posted $0.35 earnings per share. research analysts anticipate that Vertex Pharmaceuticals will post 1.67 EPS for the current fiscal year.
Vertex Pharmaceuticals announced that its Board of Directors has approved a share buyback program on Wednesday, January 31st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the pharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.
In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 46,172 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $158.65, for a total value of $7,325,187.80. Following the completion of the sale, the executive vice president now directly owns 57,835 shares of the company’s stock, valued at $9,175,522.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paul M. Silva sold 9,883 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $173.50, for a total value of $1,714,700.50. Following the completion of the sale, the senior vice president now directly owns 25,228 shares of the company’s stock, valued at $4,377,058. The disclosure for this sale can be found here. Insiders have sold 356,966 shares of company stock worth $57,081,624 over the last quarter. 1.80% of the stock is currently owned by corporate insiders.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.